4 S&P 500 Dividend Stocks Paying Shareholders More Than Their Free Cash Flow

Published November 19, 2026, 7:17am ET · 4 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Stock Market Trader Working Investment Charts, Graphs, Ticker, Diagrams Projected on His Face and Reflecting in Glasses. Financial Analyst and Digital Businessman Selling Shorts and Buying Longs
© Gorodenkoff / Shutterstock.com

Income investors like Pfizer (NYSE:PFE | PFE Price Prediction), which yields 6.108%, the kind of number they look for. In the first nine months of 2026, though, its free cash flow was $7,283 million, while it paid out $7,347 million in dividends. A high yield is only as good as the company’s ability to keep paying it, and four well-known S&P 500 names are writing dividend checks their cash flow hasn’t been able to cover.

Free cash flow is the cash a business has left after paying its operating costs and the capital spending needed to run it. That money is what actually funds a dividend. When the dividend is higher, the company must fill the gap with debt, asset sales, or cash reserves. None of those options lasts forever. The test is simple. Compare dividends paid with free cash flow, check the debt trend, and decide whether the shortfall is a temporary dip or a permanent decline.

Pfizer (PFE): A 6% Yield Facing a Patent Cliff

Pfizer pays $0.43 per quarter, or $1.72 a year, after annual increases from $0.34 in 2018. That attractive yield also reflects a 27.56% drop in share price over five years.

The cash shortfall goes back further than 2026. In 2025, free cash flow was $9,076 million against $9,771 million in dividends. In the second quarter of 2026, it generated just $302 million of free cash flow while paying out $2,451 million. Measured against trailing GAAP EPS of $0.70, the payout ratio is about 246%, weighed down by a $3.8B[1] impairment after a failed Phase 3 trial. Net debt stands at 2.76 times EBITDA, and management assumes a ~$1.1B[2] revenue hit from generics and biosimilars, with the risk of generic competition for Eliquis still ahead. Pfizer cut its dividend once before, from $0.32 to $0.16 in 2009.

On the positive side, adjusted EPS guidance of $2.95 to $3.05[2] covers the payout, and third-quarter operating cash flow rose to $5,375 million. With no buybacks planned in 2026, spare cash is going toward paying down debt.

United Parcel Service (UPS): Dividend Checks Larger Than the Cash Coming In

United Parcel Service (NYSE:UPS) yields 5.92% on a $6.56 annual payout, and the records show no reduction going back to 2008. The stock has gained 27.21% over the past year but is still down 31.9% over five years.

The dividend equals about 126% of trailing EPS of $5.19. Free cash flow was $4,765 million in 2025 against $5,398 million in dividends, and $3,765 million through nine months of 2026 against $4,064 million. Annual operating cash flow fell from $14,104 million in 2022 to $8,450 million in 2025. Cash on hand fell from $5.887B to $4.653B[3] over six months, and U.S. average daily volume slid to 15,621 thousand[4] pieces.

Management expects ~$6.1B[4] of adjusted free cash flow this year against ~$5.4B in dividends. That is a thin buffer while UPS also spends $1.4 to $1.6B[4] on transformation and contributes $1.3B to pensions. If restructuring costs decline and pricing holds, the gap may close.

3M (MMM): Litigation Payments Draining the Cash Cushion

3M (NYSE:MMM) yields only 1.69%, but it shows that a modest yield still depends on cash. The company already cut its quarterly dividend from $1.51 to $0.70 in 2024 and has since raised it to $0.78.

Free cash flow was $638 million in 2024 against $1,982 million in dividends, and $1,396 million in 2025 against $1,562 million. In the third quarter of 2026, $1.0B[5] in PFAS payments cut operating cash flow by 72.3%, leaving $230 million of free cash flow against $403 million in dividends. Financing brought in $3.483B[5] that quarter, and shareholders’ equity fell 9.92% to $4.169B.

Management guides to about $4.8B[5] of adjusted free cash flow. The gap between that adjusted figure and the GAAP cash flow left after litigation payments is the number to track.

Dow (DOW): Already Cut Once, Still at the Mercy of the Cycle

Dow (NYSE:DOW) yields 4.38% after halving its quarterly payout from $0.70 to $0.35 in 2025. Investors who held through the stress in 2024 and 2025 still got the cut.

In 2025, operating cash flow of $1,032 million did not cover capital spending, producing free cash flow of -$1,447 million while the company paid $1,490 million in dividends. Trailing EPS remains at -$1.29, and the stock is down 30.48% over five years.

The smaller dividend is now covered: nine-month free cash flow of $2,452 million compares with $758 million paid out. That buffer depends on polyethylene prices, which rose 30%[6] year over year in the second quarter, partly because the Middle East conflict reduced supply. If prices decline, the shortfall could return.

What Retirees Should Watch Before Trusting These Payouts

Track quarterly dividends paid against free cash flow, watch whether debt is rising to fill the gap, and check whether adjusted cash flow guidance turns into real GAAP cash. A dividend cut usually sends the stock falling, so investors can lose income and principal at the same time. Yield alone is never a reason to buy a stock (we outlined red flags that a big payout is about to be cut in a free report: Dividend Traps).

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →

Sources

  1. Pfizer Form 8-K (Q2 FY2026)U.S. Securities and Exchange Commission
  2. Pfizer Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  3. United Parcel Service Form 8-K (Q2 FY2026)U.S. Securities and Exchange Commission
  4. United Parcel Service Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  5. 3M Company Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  6. Dow Form 8-K (Q2 FY2026)U.S. Securities and Exchange Commission